Research projects
Start of main content
Novel immunotherapeutic strategies against T-ALL, a rare pediatric disease
19th national competition for scientific and technical research
Rare diseases

Senior Researcher : María Luisa Toribio García
Research Centre or Institution : Centro de Biología Molecular "Severo Ochoa". CSIC-Universidad Autónoma de Madrid
Abstract
Preliminary results from our lab support the hypothesis that a protein complex termed preTCR, which is transiently expressed during the development of T lymphocytes, may be an optimal target for the development of a safe, specific, and efficacious immunotherapy based on CAR-T cells against T-cell acute lymphoblastic leukemia (T-ALL), a rare disease mostly affecting children. To confirm this hypothesis, our project has approached the following specific aims: 1) to define the functional relevance of pre-TCR as a T-ALL biomarker; 2) to develop anti-preTCR CAR-engineered T cells confirming their function in vitro, and 3) to validate a T-ALLtargeted immunotherapy based on pre-TCR-specific CAR-T cells in preclinical in vivo assays.
Based on molecular biology strategies, functional in vitro approaches and patientderivedT-ALL xenotransplantation (PDX) mouse models, we have confirmed our initial hypothesis and showed that:
1) Pre-TCR is a biomarker of cells with leukemia-initiating potential in >50% of TALL patients.
2) Pre-TCR targeting with a specific anti-preTCR (anti-pTa) monoclonal antibody (mAb) has therapeutic impact in PDX models in vivo, hampering T-ALL progression and increasing overall mouse survival.
3) The scFv fragment derived from the anti-pTa mAb allowed to generate a preTCRspecific 2nd-generation CAR (CD8α-4-1BB-CD3ζ) that is properly expressed on the surface of transduced primary human T cells.
4) Anti-pre-TCR specificity of our engineered CAR-T cells has been confirmed in functional activation and antibody blocking assays in vitro.
5) We have validated the cytolytic function of anti-preTCR CAR-engineered T cells in functional assays in vitro.
6) In vivo PDX preclinical assays have validated the efficacy of the proposed preTCR-specific CAR-T immunotherapy showing an increased overall survival of treated mice.
In conclusion, results derived from this project provide direct evidence that preTCRspecific CAR-T immunotherapy may be an efficient strategy for treatment of a high proportion of T-ALL patients.
Scientific Production |
|
---|---|
Magazine Articles | 3 |
Communications at national conferences | 4 |
Communications at international conferences | 5 |
-
Activities related
-
Projects related
-
News related
-
Publications related
-
4
Jun
2019
International Symposium Genomic Medicine Madrid, Tuesday and Wednesday, June 4 and 5, 2019 9:30 hours
-
27
Nov
2019
International Symposium Undiagnosed and rare diseases in children and adolescents: Translation to clinic and society Barcelona, Wednesday and Thursday, November 27 and 28, 2019 9:30 hours
-
30
Jan
2020
International Symposium Understanding and reprogramming developmental visual disorders: from anophthalmia to cortical impairments Madrid, Thursday and Friday, 30 and 31 January 2020, 9:30 hours
- Systemic analysis of the gene regulatory networks involved in the specification and maintenance of the retinal pigment epithelium: towards new therapies for retinal degenerative diseases 2016 Senior Researcher : Paola Bovolenta Nicolao Research Centre or Institution : Centro de Biología Molecular "Severo Ochoa". CSIC-Universidad Autónoma de Madrid
- Molecular basis of immune deficiency in Wolf-Hirschhorn Syndrome (4p-) 2016 Senior Researcher : César Cobaleda Hernández Research Centre or Institution : Centro de Biología Molecular "Severo Ochoa". CSIC-Universidad Autónoma de Madrid
- AGC1 deficiency and calcium signaling in mitochondria: a new disease model for the study of pathogenic mechanisms and for the development of therapeutic strategies 2016 Senior Researcher : Jorgina Satrústegui Gil-Delgado Research Centre or Institution : Centro de Biología Molecular "Severo Ochoa". CSIC-Universidad Autónoma de Madrid
-
-
Expertos piden ampliar la prueba del talón a más enfermedades
Published on 01/15/2019
End of main content